Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines

Basit Öğe Kaydı
dc.contributor.authorAzmi, Soraya
dc.contributor.authorAljunid, Syed Mohamed
dc.contributor.authorMaimaiti, Namaitijiang
dc.contributor.authorAli, Al-Abed
dc.contributor.authorNur, Amrizal Muhammad
dc.contributor.authorDe Rosas-Valera, Madeleine
dc.contributor.authorEncluna, Joyce
dc.date.accessioned2024-02-23T14:03:11Z
dc.date.available2024-02-23T14:03:11Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractObjectives: To describe the incidence, mortality, cost, and length of stay (LOS) of hospitalized community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in three Southeast Asian countries: Malaysia, Indonesia, and the Philippines. Methods: Using Casemix system data from contributing hospitals, patients with International Classification of Diseases 10th revision (ICD-10) codes identifying pneumonia were categorized into CAP or HAP using a logical algorithm. The incidence among hospitalized patients, case fatality rates (CFR), mean LOS, and cost of admission were calculated. The population incidence was calculated based on Malaysian data. Results: For every 100 000 discharges, CAP and HAP incidences were 14 245 and 5615 cases, respectively, in the Philippines, 4205 and 2187, respectively, in Malaysia, and 988 and 538, respectively, in Indonesia. The impact was greatest in the young and the elderly. The CFR varied from 1.4% to 4.2% for CAP and from 9.1% and 25.5% for HAP. The mean LOS was 6.1-8.6 days for CAP and 6.9-10.2 days for HAP. The cost of hospitalization was between USD 254 and USD 1208 for CAP and between USD 275 and USD 1482 for HAP. Conclusions: The burden of CAP and HAP is high. Results varied between the three countries, likely due to differences in socio-economic conditions, health system differences, and ICD-coding practices. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.en_US
dc.description.sponsorshipPfizer (Malaysia) Sdn Bhd.en_US
dc.description.sponsorshipThis study was funded by Pfizer (Malaysia) Sdn Bhd.en_US
dc.identifier.doi10.1016/j.ijid.2016.05.021
dc.identifier.endpage93en_US
dc.identifier.issn1201-9712
dc.identifier.issn1878-3511
dc.identifier.pmid27235085en_US
dc.identifier.scopus2-s2.0-84975486569en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage87en_US
dc.identifier.urihttps://doi.org/10.1016/j.ijid.2016.05.021
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12006
dc.identifier.volume49en_US
dc.identifier.wosWOS:000380806600014en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofInternational Journal Of Infectious Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCapen_US
dc.subjectHapen_US
dc.subjectBurden Of Diseaseen_US
dc.subjectIncidence Rateen_US
dc.subjectLosen_US
dc.subjectCosten_US
dc.titleAssessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippinesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu